Critical appraisal of the role of recombinant activated factor VII in the treatment of hemophilia patients with inhibitors

Hemophilia patients with inhibitors faced the constraint of inadequate treatment for several years before the era of recombinant factor VIIa (rFVII). Initially, rFVIIa was used in the compassionate-use programs. After a worldwide license was issued, more than 1.5 million doses were administered. Ble...

Descripción completa

Detalles Bibliográficos
Autores principales: Chuansumrit, Ampaiwan, Angchaisuksiri, Pantep, Sirachainan, Nongnuch
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2010
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3262327/
https://www.ncbi.nlm.nih.gov/pubmed/22282682

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3262327/
https://www.ncbi.nlm.nih.gov/pubmed/22282682

Ejemplares similares